Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.271 USD | -1.09% | +0.37% | -88.52% |
May. 09 | GlycoMimetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 07 | Capital One Downgrades GlycoMimetics to Equalweight, Price Target at $0.50 | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 2.67M | Capitalization | 17.47M |
---|---|---|---|---|---|
Net income 2024 * | -40M | Net income 2025 * | -41M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 6.54 x |
P/E ratio 2024 * |
-0.43
x | P/E ratio 2025 * |
-0.54
x | Employees | 35 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.92% |
Latest transcript on GlycoMimetics, Inc.
1 day | -1.09% | ||
1 week | +0.37% | ||
1 month | -83.27% | ||
3 months | -91.00% | ||
6 months | -84.24% | ||
Current year | -88.52% |
Managers | Title | Age | Since |
---|---|---|---|
Harout Semerjian
CEO | Chief Executive Officer | 52 | 21-08-05 |
Rachel King
FOU | Founder | 64 | 03-04-03 |
Brian Hahn
DFI | Director of Finance/CFO | 49 | 10-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Daniel Junius
BRD | Director/Board Member | 71 | 16-03-16 |
Patricia Andrews
BRD | Director/Board Member | 66 | 17-06-11 |
Scott Jackson
BRD | Director/Board Member | 59 | 18-11-27 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 0.271 | -1.09% | 396,856 |
24-05-30 | 0.274 | +6.82% | 885,398 |
24-05-29 | 0.2565 | -3.93% | 535,629 |
24-05-28 | 0.267 | -1.11% | 666,894 |
24-05-24 | 0.27 | -1.17% | 980,533 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-88.52% | 17.47M | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- GLYC Stock